HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $41 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edward White has reiterated a Buy rating on Syndax Pharmaceuticals (NASDAQ:SNDX) and maintained a price target of $41.
January 02, 2024 | 5:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Edward White reaffirmed a Buy rating on Syndax Pharmaceuticals with a $41 price target.
The reiteration of a Buy rating and the maintenance of a $41 price target by a reputable analyst could lead to increased investor confidence and a potential short-term positive impact on SNDX's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100